Two deaths reported in Japan in patients receiving liraglutide
This article was originally published in Scrip
Novo Nordisk has informed the regulatory authorities and medical professionals in Japan of the deaths of two patients who had been administered the company's novel antidiabetic Victoza (liraglutide).
You may also be interested in...
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.